Unsolicited Adverse Event
Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law
Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A